Affinity Asset Advisors LLC Invests $1.95 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Affinity Asset Advisors LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 150,000 shares of the company’s stock, valued at approximately $1,952,000. Affinity Asset Advisors LLC owned about 0.24% of Viridian Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of VRDN. Ameritas Investment Partners Inc. increased its position in Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after purchasing an additional 799 shares during the last quarter. Swiss National Bank raised its holdings in shares of Viridian Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 67,200 shares of the company’s stock valued at $1,464,000 after purchasing an additional 800 shares in the last quarter. Principal Financial Group Inc. boosted its position in Viridian Therapeutics by 9.7% during the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock valued at $209,000 after purchasing an additional 1,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after acquiring an additional 1,135 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $21.17 on Wednesday. Viridian Therapeutics, Inc. has a fifty-two week low of $10.93 and a fifty-two week high of $24.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82. The stock’s fifty day moving average is $16.52 and its two-hundred day moving average is $15.11.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. Equities analysts forecast that Viridian Therapeutics, Inc. will post -3.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRDN has been the topic of several recent analyst reports. Wolfe Research started coverage on Viridian Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a report on Thursday, September 19th. The Goldman Sachs Group lifted their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Viridian Therapeutics in a report on Monday, July 29th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.30.

Insiders Place Their Bets

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 1,600,000 shares of the stock in a transaction dated Friday, September 13th. The stock was acquired at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.65% of the stock is owned by insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.